Xeris Biopharma Holdings Inc

Xeris Biopharma Holdings Inc

XERS

Get informed when a big investor buys or sells

+ Follow
Market Cap$1.44B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Xeris Biopharma Holdings IncXeris Biopharma Holdings Inc117.8-92%8.32.9
$2.89

Current Fair Value

65.1% downside

Overvalued by 65.1% based on the discounted cash flow analysis.

Share Statistics

Market cap$1.44 Billion
Enterprise Value$1.37 Billion
Dividend Yield$- (-)
Earnings per Share$0
Beta0.85
Outstanding Shares170,523,208

Return

Return on Equity92.29%ROE
Return on Assets3.06%
Return on Invested Capital11.05%

Valuation & Multiples

P/E Ratio117.8P/E Ratio
PEG-94.82PEG
Price to Sales8.28Price to Sales
Price to Book Ratio-Price to Book Ratio
Enterprise Value to Revenue4.34
Enterprise Value to EBIT45.2
Enterprise Value to Net Income113
Total Debt to Enterprise0.03
Debt to Equity2.87Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
May 14, 2026
EPS Estimate
$-0.00
Average shareholder expectation
Revenue Estimate
$80.67 M
Average shareholder expectation

Next Earnings Call

Expected Date
August 6, 2026
EPS Estimate
$0.02
Average shareholder expectation
Revenue Estimate
$90.29 M
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.0000▼ 69.46%
Total Calls-▼ 100.00%
Total Puts-▼ 100.00%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %0.13%▼ 65.45%
Total Invested$1.94M▼ 99.68%
Investors Holding4▼ 240.00%

ESG Score

No data

About Xeris Pharmaceuticals Inc

CEO: paul Edick